Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Citi raised its target price on GSK from 1535p to 1700p. The bank has now increased its core earnings per share estimates for 2030 to 2035 by between 19% and 43%. They particularly like the recent Bellus and Aiolos respiratory deals addressing de-risked targets in a core therapeutic area of competence for GSK. Citi has also raised its forecasts for ViiV - “assuming the next generation therapies with larger dosing windows translate into higher adoption rates”.
...shows Citi giving us the thumbs up after many years. Let's hope a few more big institutions come out in support and this SP finally firms up.
Some of the most robust evidence (suggesting no evidence of a link between ranitidine with cancer) was published in Sept 2023 in the The Journal of the American Medical Association (JAMA). Link below -
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509724/
I have no idea how the ambulance chasers are going to dismiss this large multinational credible study, especially as its validity is supported by the publication in a leading peer reviewed American journal.
Another unjustified drop in SP yesterday, for a hearing in Delaware we’ve known about for some time? GSKs defence seems pretty strong.. Yes, there is a theoretical risk that NDMA in ranitidine could increase the risk of cancer, hence its removal from market, but as GSK are saying (quite correctly) there is now an increasing body of robust evidence, in large real world observational studies, (since the litigation was initially raised) which show no increase in cancer rates over the PPIs, or famotidine.. (one of many papers below)
https://pubmed.ncbi.nlm.nih.gov/34251045/
I’m still at a loss to understand why such a sustained hit on the SP. You can’t win a case purely on theoretical risk, especially if the subsequent robust clinical studies have disproven the theory…IMHO of course…
Feels like everyone thinks the drop in SP is overdone , but guess we'll have to wait for the judges now to agree
Analysts finally catching on to what we have known for the past 6-12 months.
The chance to buy at under £14 was the biggest giveaway since being able to buy Shell for under £10.
UBS raises GSK to ‘buy’ rating from ‘sell’ and increase price target from 1310p to 1860p
UBS cuts AstraZeneca to ‘sell’ rating from buy reducing its price target from 13000p to 10700p.
Ahead of GSK’s full year results, the stock trades at nine times earnings, compared with sector peers who trade at a multiple of 15. They continue to view the current discount to peers as unwarranted and largely attributable to misguided assumptions on the potential cost of Zantac litigation. This has disproportionately overshadowed the improved and increasingly attractive growth story GSK delivered in 2023.
The broker has lifted its target price from 1850p to 2000p and kept a ‘buy’ rating
GSK has received a buy recommendation and a healthy price target upgrade from analysts at Deutsche Bank, which has the UK pharma as a top pick in the sector.
Deutsche Bank’s target price for GSK rises to 1850p from 1700p
Jefferies have been listening to Dame Emma.
Therefore raising of SP to 1900pence.
Like to see 1900pence SP ASAP
Stay positive - it's a new Year...
Oh christ - usually spells disaster when she opens mouth
Jeffries suggests GSK is “deeply discounted” as it lifted its recommendation to buy from hold. They estimate that GSK will pay between $3bn-$4bn to settle the Zantac litigation within the coming months. The company’s growth profile is under appreciated and the current share price offers attractive risk reward. Jeffries raises its target price on GSK by 23% to 1900 pence from 1550 pence.
Just dropping by to say hi. I bought into GSK this afternoon.
Only a small punt of 200 shares. Look forward to adding more.
Happy New Year folks.
Good to see Dame Emma on Media duties.
More is required to extoll virtues of GSK.
This could now be 'Happy New Year'for GSK holders. P.E of 9.6 ,way below other pharma average of over 20 and decent part year figures expected soon. Glad to be heavily in these right now.
Get the market to believe that our unloved Dame is moving on!!
Have you actually researched? Morningstar ratedto 17 biopharma firms , taking other factors such as current stock price and any headwinds into account beyond IRA effects. Top ratings (five stars) were GSK and Roche. Four-star firms were Merck, Sanofi, BioMarin and given its exposure to the new Medicare measures Gilead were included.
One positive factor figuring into the rating for many of these companies, is global diversification, as opposed to a heavy dependence on Medicare sales. It's not always as black and white as you may think.
This is GSK problem, capped prescription prices and back dated over charges, last quarter of this year, all that profit the usa government wants it back.. they have passed the bill. google it, does not read well..
Fewww… back to normal. Couldn’t handle the anxiety of a sudden SP turnover
This is going to hurt the big pharmaceuticals, how much is priced in ?
Or clear your cache and history and come back in - this sometimes works also.
Use Chrome or Firefox with an ad blocker. Annoying isn't it. There is a fix though.
Wow .. even GSK is blue today, incredible, will it stay blue until until noon?
I don't get it ,this should be above 18 pounds ,,as pipelines are get results
Remember the stock market is fickle. What we do know is there have been Getting ahead of Infectious Disease, HIV and Respiratory Disease with GSK management presentations with Oncology to come next year. Peak Year Sales for late stage assets have been stated as follows :
RSV. £3bn
Men ABCWY. £2bn
Gepotidacin, tebi & Brexafemme. £2bn
HBVASO. £2bn
Pneumococcal £4bn
Cabenuva/Prep. £2bn
Depemokimab. £3bn
Camlipixant. £2.5bn
Nucala COPD. £1bn
Assuming no change from two years ago for Jemperli and half the sales for Zejula and nothing for Blenrep (v conservative given Dream 7 last week)
Jemperli £2bn
Zejula. £1bn
Assume Ojjaara £1.5bn
Total PYS of £21-26bn across a number of assets. We also know the SP will go nowhere until Zantac litigation is resolved. If management can resolve Zantac next year and start to deliver on the pipeline the future is brighter than the current SP would suggest.